An expert in immunology, Bernard Maillère is currently the director of the laboratory of immunochemistry of cellular immune response at the Institute of Biology and Technologies (Commissariat a l’Energie Atomique, FR). His laboratory has developed an original platform to evaluate cellular immune responses of therapeutic vaccine candidates in humans, and to identify T-cell epitopes. He identified and patented several new HLA class II restricted epitopes from various viruses and tumors. Notably, peptides from HIV, hepatitis C and tumor antigens have been discovered by Dr. Maillère, and constitute several Vaxeal immunotherapy candidates.
Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance. The Board also brings a wealth of diverse corporate and M&A experience.
Vaxeal’s pre-eminent Scientific Advisory Board advises the company in the fields of immunology, immunotherapy, clinical immuno-oncology, infectious diseases and regulatory affairs.